A share price of Haemonetics Corp. [HAE] is currently trading at $75.61, down -1.22%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The HAE shares have gain 4.36% over the last week, with a monthly amount glided 1.02%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Haemonetics Corp. [NYSE: HAE] stock has seen the most recent analyst activity on September 13, 2024, when CL King initiated its Buy rating and assigned the stock a price target of $116. Previously, BofA Securities started tracking the stock with Neutral rating on September 11, 2024, and set its price target to $85. On September 10, 2024, BTIG Research initiated with a Buy rating and assigned a price target of $112 on the stock. Needham upgraded its rating to a Buy but stick to its price target of $112 on June 12, 2024. Mizuho initiated its recommendation with a Buy and recommended $90 as its price target on October 13, 2022. Needham downgraded its rating to Hold for this stock on January 27, 2022. In a note dated December 15, 2021, Citigroup downgraded an Neutral rating on this stock and revised its target price from $75 to $59.
Haemonetics Corp. experienced fluctuations in its stock price throughout the past year between $70.74 and $97.97. Currently, Wall Street analysts expect the stock to reach $104.33 within the next 12 months. Haemonetics Corp. [NYSE: HAE] shares were valued at $75.61 at the most recent close of the market. An investor can expect a potential return of 37.98% based on the average HAE price forecast.
Analyzing the HAE fundamentals
Trailing Twelve Months sales for Haemonetics Corp. [NYSE:HAE] were 1.33B which represents 7.98% growth. Gross Profit Margin for this corporation currently stands at 0.51% with Operating Profit Margin at 0.13%, Pretax Profit Margin comes in at 0.11%, and Net Profit Margin reading is 0.09%. To continue investigating profitability, this company’s Return on Assets is posted at 0.05, Equity is 0.12 and Total Capital is 0.08. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.35.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 74.90 points at the first support level, and at 74.19 for the second support level. However, for the 1st resistance point, the stock is sitting at 76.43, and for the 2nd resistance point, it is at 77.25.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Haemonetics Corp. [NYSE:HAE] is 3.76. As well, the Quick Ratio is 2.33, while the Cash Ratio is 1.32. Considering the valuation of this stock, the price to sales ratio is 2.90, the price to book ratio is 4.27 and price to earnings (TTM) ratio is 33.87.
Transactions by insiders
Recent insider trading involved Strong Stewart W, President, Global Hospital, that happened on Jul 26 ’24 when 4312.0 shares were sold. Officer, Strong Stewart W completed a deal on Jul 26 ’24 to buy 4312.0 shares. Meanwhile, EVP, Chief Technology Officer Lingamneni Anila sold 2136.0 shares on Jul 11 ’24.
